GO:1904031 positive regulation of cyclin-dependent protein kinase activity: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904031 describes any process that activates or increases the frequency, rate or extent of cyclin-dependent protein kinase (CDK) activity.
• CDK activation is driven by cyclin binding, activating phosphorylation by CDK-activating kinase (CAK), and removal of inhibitory phosphorylations.
• MYC and E2F transcription factors amplify CDK gene expression, creating positive feedback loops that reinforce CDK activity.
• Dysregulated CDK activation is a hallmark of cancer, and CDK4/6 inhibitors are standard therapies in hormone receptor-positive breast cancer.
• CDK7 and CDK8/19 control transcriptional CDK activity and are emerging therapeutic targets in multiple myeloma and other cancers.
• CRISPR knockout, point-mutation knock-in, and overexpression models are essential to dissect causal roles of CDK regulators.
Description
Cyclin-dependent protein kinases (CDKs) are serine/threonine kinases that drive cell cycle progression and transcription by phosphorylating key substrates such as the retinoblastoma protein (RB). The Gene Ontology term GO:1904031, positive regulation of cyclin-dependent protein kinase activity, captures all molecular events that enhance CDK catalytic output, including cyclin binding, activating phosphorylation, and relief from inhibitory constraints. This term is critical for researchers because CDK hyperactivation is a central oncogenic mechanism, and understanding its positive regulators informs both cancer biology and therapeutic targeting. The process is highly conserved and tightly integrated with transcriptional programs controlled by MYC and E2F, which themselves are downstream targets of CDK activity, forming feed-forward loops. In this article, we synthesize authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of GO:1904031, its key genes, disease relevance, and experimental models for functional studies.
positive regulation of cyclin-dependent protein kinase activity At A Glance
| GO ID | GO:1904031 |
|---|---|
| GO term | positive regulation of cyclin-dependent protein kinase activity |
| Ontology | biological_process |
| Synonym | activation of cyclin-dependent protein kinase activity; up regulation of cyclin-dependent protein kinase activity; up-regulation of cyclin-dependent protein kinase activity; upregulation of cyclin-dependent protein kinase activity |
| Major function | Enhances CDK catalytic activity to promote cell cycle progression and transcriptional regulation. |
| Key regulators | Cyclins (e.g., CCND1, CCNE1), CAK complex (CDK7/CCNH/MNAT1), and CKIs (e.g., p16, p21). |
| Disease relevance | Cancer, senescence, and resistance to CDK4/6 inhibitors. |
| Research methods | CRISPR KO/point mutation/knock-in, phosphoproteomics, cell cycle analysis. |
What Is GO:1904031?
GO:1904031 is a biological process term defined as any process that activates or increases the frequency, rate or extent of cyclin-dependent protein kinase activity. In practical terms, it encompasses the molecular events that elevate CDK catalytic function, such as cyclin binding, activating phosphorylation by CAK, and inhibition of CDK inhibitors (CKIs).
Why Is positive regulation of cyclin-dependent protein kinase activity Important in Cell Biology?
Positive regulation of CDK activity is a fundamental control point in cell proliferation and transcription, and its dysregulation is causally linked to cancer, senescence, and therapy resistance. Understanding GO:1904031 provides mechanistic insight into how oncogenes such as MYC and CCND1 drive uncontrolled proliferation, and how CDK inhibitors achieve clinical benefit. Moreover, emerging evidence links CDK activation to immune surveillance and salt stress responses in plants, underscoring its broad biological significance.
• Drives G1/S and G2/M cell cycle transitions by phosphorylating RB and other substrates.
• Amplifies oncogenic transcription via CDK7-mediated phosphorylation of RNA polymerase II.
• Mediates resistance to CDK4/6 inhibitors through cyclin E1 overexpression or CDK2 activation.
• Regulates senescence and immune surveillance via p16-dependent PD-L1 stabilization.
• Controls plant salt tolerance through CDK8-AHL10-SUVH2/9 module.
• Provides therapeutic targets for multiple myeloma and triple-negative breast cancer.
• Serves as a biomarker for cell proliferation in cancer diagnostics.
• Enables synthetic lethality approaches with CDK inhibitors in combination therapies.
What Happens During positive regulation of cyclin-dependent protein kinase activity?
Cyclin Binding and CDK Activation
In simple terms: Cyclins act like keys that turn on CDK enzymes.
The primary mechanism for positive regulation of CDK activity is the binding of a regulatory cyclin subunit to the catalytic CDK subunit. Cyclin D binds CDK4/6 to initiate G1 phase progression, while cyclin E activates CDK2 for G1/S transition. This binding induces conformational changes that align the catalytic cleft and displace the activation segment, enabling substrate phosphorylation.
Activating Phosphorylation by CAK
In simple terms: A kinase called CAK adds a phosphate that fully activates CDKs.
Full activation of CDKs requires phosphorylation of a conserved threonine residue in the T-loop by the CDK-activating kinase (CAK) complex, composed of CDK7, cyclin H, and MAT1. This phosphorylation is essential for CDK2, CDK4, and CDK6 activity and is a key node of positive regulation.
Relief from Inhibitory Phosphorylation
In simple terms: Removing inhibitory phosphates also boosts CDK activity.
CDKs are inhibited by phosphorylation at Thr14 and Tyr15 by Wee1 and Myt1 kinases. The CDC25 family of phosphatases removes these inhibitory marks, thereby positively regulating CDK activity. This dephosphorylation is a critical step for mitotic entry and is often dysregulated in cancer.
Transcriptional Amplification by MYC and E2F
In simple terms: MYC and E2F increase the production of cyclins and CDKs.
MYC and E2F transcription factors directly induce the expression of cyclins (CCND1, CCNE1) and CDKs (CDK4, CDK2), creating a feed-forward loop that amplifies CDK activity. This transcriptional positive regulation is a hallmark of proliferating cells and is frequently hijacked in cancer.
Inhibition of CDK Inhibitors (CKIs)
In simple terms: Removing brakes on CDKs also counts as positive regulation.
CKIs such as p16INK4A, p21CIP1, and p27KIP1 bind and inhibit CDK-cyclin complexes. Positive regulation of CDK activity can occur indirectly through degradation or sequestration of CKIs, for example by CDK4/6-mediated phosphorylation of p21 or p27, which leads to their cytoplasmic retention or degradation.
Key Genes Involved in GO:1904031 positive regulation of cyclin-dependent protein kinase activity
The following genes and proteins are central to the positive regulation of cyclin-dependent protein kinase activity, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCND1 | Binds and activates CDK4/6 | Overexpressed in breast cancer; target for CDK4/6 inhibitors |
| CCNE1 | Activates CDK2 | Amplification causes resistance to CDK4/6 inhibitors |
| CDK4 | Catalytic subunit activated by cyclin D | Primary target of palbociclib, ribociclib |
| CDK6 | Catalytic subunit activated by cyclin D | Target of CDK4/6 inhibitors; resistance mechanisms |
| CDK2 | Catalytic subunit activated by cyclin E/A | Key mediator of cell cycle progression and resistance |
| CDK7 | CAK catalytic subunit; activates CDKs | Transcriptional CDK; target in multiple myeloma |
| CCNH | Regulatory subunit of CAK | Required for CDK7 activity |
| MNAT1 | Assembly factor for CAK | Stabilizes CDK7-cyclin H complex |
| MYC | Transcription factor inducing cyclins and CDKs | Oncogene driving CDK activation |
| E2F1 | Transcription factor inducing CDK genes | Mediates G1/S transition |
| CDC25A | Phosphatase removing inhibitory phosphates | Positively regulates CDK2 |
| CDC25C | Phosphatase activating CDK1 | Regulates mitotic entry |
| WEE1 | Kinase adding inhibitory phosphorylation | Negative regulator; target for cancer therapy |
| CDKN2A (p16) | Inhibits CDK4/6 | Loss causes CDK hyperactivation; regulates senescence |
| CDKN1A (p21) | Inhibits CDK2/4 | Mediates p53-dependent cell cycle arrest |
| CDKN1B (p27) | Inhibits CDK2/4 | Regulates G1 progression; often downregulated in cancer |
| CDK8 | Transcriptional CDK; regulates salt stress | Plant CDK8-AHL10 module in salt tolerance |
| CDK19 | Paralog of CDK8 | Transcriptional regulation; emerging target |
How Is positive regulation of cyclin-dependent protein kinase activity Regulated?
Positive regulation of CDK activity is controlled at multiple levels. Upstream mitogenic signals activate the RAS-MAPK and PI3K-AKT pathways, which induce cyclin D expression and promote CDK4/6 activation. The CAK complex (CDK7-CCNH-MNAT1) provides activating phosphorylation, while CDC25 phosphatases remove inhibitory marks. Conversely, CKIs (p16, p21, p27) and WEE1 kinase provide negative regulation. In cancer, this balance is frequently disrupted by cyclin amplification, CKI loss, or CDK7 overexpression, leading to constitutive CDK activity. Additionally, CDK8/19 modules regulate transcriptional responses to environmental stress, such as salt tolerance in plants.
positive regulation of cyclin-dependent protein kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCND1 | Breast cancer, mantle cell lymphoma | Knockout in cancer cell lines; overexpression in normal cells |
| CDKN2A | Melanoma, pancreatic cancer, senescence | Point mutation knock-in to mimic loss-of-function |
| CCNE1 | Ovarian cancer, CDK4/6 inhibitor resistance | Overexpression model in breast cancer cells |
| CDK7 | Multiple myeloma, transcriptional addiction | Knockout or point mutation in myeloma cell lines |
| CDK8 | Plant salt tolerance | Arabidopsis knockout and point mutation |
Cancer and CDK Hyperactivation
Dysregulated positive regulation of CDK activity is a hallmark of cancer. CCND1 amplification, CDKN2A loss, and CCNE1 overexpression drive constitutive CDK4/6 and CDK2 activity, promoting uncontrolled proliferation. CDK4/6 inhibitors are standard of care in HR-positive breast cancer, but resistance frequently emerges through cyclin E1 upregulation or CDK2 activation. CDK7 inhibition is being explored in multiple myeloma to target transcriptional addiction.
Senescence and Immune Surveillance
p16-dependent CDK4/6 inhibition induces senescence, and recent work shows that p16 increases PD-L1 stability to regulate immunosurveillance of senescent cells. This links positive regulation of CDK activity to immune evasion and suggests that CDK inhibitors may modulate anti-tumor immunity.
Therapeutic Resistance Mechanisms
Resistance to CDK4/6 inhibitors involves multiple mechanisms, including loss of RB, cyclin E1 amplification, and activation of CDK2 or CDK7. Understanding positive regulation of CDK activity is therefore critical for developing next-generation inhibitors and combination strategies.
Plant Stress Responses
In Arabidopsis, salt stress activates the CDK8-AHL10-SUVH2/9 module to dynamically regulate salt tolerance, demonstrating that positive regulation of CDK activity extends beyond cell cycle control to environmental stress adaptation.
From positive regulation of cyclin-dependent protein kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CCND1 amplification drive CDK4/6 inhibitor resistance? | Overexpression of CCND1 in sensitive breast cancer cells |
| Is CDK7 kinase activity required for MYC-driven transcription? | Point mutation of CDK7 catalytic residue (D155A) |
| Does p16 loss increase PD-L1 stability? | CDKN2A knockout in senescent cells |
| Can CDK2 activation bypass CDK4/6 inhibition? | Knock-in of constitutively active CDK2 mutant |
| What is the role of CDK8 in salt tolerance? | Arabidopsis cdk8 knockout and point mutation |
| Does cyclin E1 overexpression cause resistance? | Knock-in of CCNE1 under endogenous promoter |
How to Study the positive regulation of cyclin-dependent protein kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Global phosphorylation changes | Identify CDK substrates and activation loops |
| Flow cytometry | Cell cycle distribution | Assess proliferation and G1/S transition |
| RNA-seq | Transcriptional changes | Map E2F/MYC target gene expression |
| CRISPR knockout screen | Gene essentiality and regulators | Discover novel CDK activators |
| Western blot | Protein expression and phosphorylation | Validate CDK activation status |
| Immunoprecipitation | Protein-protein interactions | Detect cyclin-CDK complex formation |
| Kinase activity assay | CDK catalytic activity | Measure effects of positive regulators |
| Proximity ligation assay | In situ protein interactions | Visualize cyclin-CDK binding |
Phosphoproteomics for CDK Substrate Identification
Phosphoproteomics enables global mapping of CDK substrate phosphorylation. By comparing wild-type and CDK-knockout cells, researchers can identify specific sites regulated by CDK activity. This method is particularly useful for understanding how positive regulators such as cyclin D or CAK modulate substrate specificity.
Cell Cycle Analysis by Flow Cytometry
Flow cytometry with DNA dyes (e.g., propidium iodide) and EdU incorporation measures cell cycle distribution and proliferation. Positive regulation of CDK activity correlates with increased S-phase entry and G2/M progression, making this a standard readout.
Transcriptional Profiling by RNA-seq
RNA-seq reveals how CDK activation alters gene expression programs, including E2F and MYC target genes. This is essential for understanding feed-forward loops in CDK regulation.
CRISPR-Based Functional Genomics
Genome-wide CRISPR knockout or activation screens identify positive regulators of CDK activity. These screens can uncover novel cyclins, CAK components, or phosphatases that modulate CDK function.
How CRISPR Can Be Used to Study GO:1904031 positive regulation of cyclin-dependent protein kinase activity
Knockout
CRISPR knockout of positive regulators such as CCND1, CDK4, or CDK7 abolishes CDK activity and causes cell cycle arrest. This approach is used to validate essentiality and to identify resistance mechanisms.
Point Mutation
Point mutation knock-in of catalytic-dead CDK7 (D155A) or phosphorylation-deficient CDK mutants allows precise dissection of activation mechanisms without affecting protein levels.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) at endogenous CDK loci enables live-cell imaging of CDK localization and dynamics. Knock-in of constitutively active mutants (e.g., CDK2 T160E) mimics positive regulation.
Overexpression
Overexpression of cyclins (CCND1, CCNE1) or CAK components (CDK7, CCNH) drives constitutive CDK activation and is used to model oncogenic transformation and drug resistance.
How EDITGENE Supports positive regulation of cyclin-dependent protein kinase activity Research
Researchers studying positive regulation of cyclin-dependent protein kinase activity-related genes often need to determine whether a candidate gene is causally involved in CDK activation, cell cycle progression, or therapeutic resistance. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of cyclin-dependent protein kinase activity research.
Frequently Asked Questions About positive regulation of cyclin-dependent protein kinase activity
What is GO:1904031?
GO:1904031 is the Gene Ontology term for positive regulation of cyclin-dependent protein kinase activity, describing any process that increases CDK catalytic activity.
What genes are involved in positive regulation of CDK activity?
Key genes include CCND1, CCNE1, CDK4, CDK6, CDK2, CDK7, CCNH, MNAT1, MYC, E2F1, and CDC25 phosphatases.
How is CDK activity positively regulated?
Through cyclin binding, activating phosphorylation by CAK, removal of inhibitory phosphates by CDC25, and transcriptional induction by MYC/E2F.
What diseases are linked to CDK hyperactivation?
Cancer, including breast cancer, multiple myeloma, and melanoma, as well as senescence and immune evasion.
What are CDK4/6 inhibitors?
Drugs like palbociclib that block CDK4/6 activity and are used in HR-positive breast cancer, but resistance can occur via cyclin E1.
How can CRISPR help study CDK regulation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of CDK regulator function.
What is the role of CDK7 in CDK activation?
CDK7 is the catalytic subunit of CAK, which phosphorylates and activates other CDKs, and also regulates transcription.
What is p16 and how does it affect CDK activity?
p16INK4A inhibits CDK4/6; its loss increases CDK activity and is linked to senescence and cancer.
Can CDK activity be regulated in plants?
Yes, the CDK8-AHL10-SUVH2/9 module regulates salt tolerance in Arabidopsis.
What methods are used to study positive regulation of CDK activity?
Phosphoproteomics, flow cytometry, RNA-seq, CRISPR screens, and kinase assays are commonly used.
Conclusion
GO:1904031, positive regulation of cyclin-dependent protein kinase activity, is a central biological process that governs cell proliferation, transcription, and stress responses. Its dysregulation is causally linked to cancer, therapy resistance, and immune evasion, making it a prime target for therapeutic intervention. Advances in CRISPR-based models and multi-omics approaches continue to unravel the complex regulatory networks that control CDK activity, offering new opportunities for drug discovery and precision medicine.
References
- 1. Bretones G et al.. 2015. Myc and cell cycle control.. Biochim Biophys Acta 1849(5):506-16 PMID: 24704206
- 2. Majewska J et al.. 2024. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells.. Nat Cell Biol 26(8):1336-1345 PMID: 39103548
- 3. Bertoli C et al.. 2013. Control of cell cycle transcription during G1 and S phases.. Nat Rev Mol Cell Biol 14(8):518-28 PMID: 23877564
- 4. Guo P et al.. 2025. Salt stress activates the CDK8-AHL10-SUVH2/9 module to dynamically regulate salt tolerance in Arabidopsis.. Nat Commun 16(1):2454 PMID: 40074748
- 5. Asciolla JJ et al.. 2025. Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer.. Nat Cancer 6(1):24-40 PMID: 39885369
- 6. Cheung A et al.. 2024. Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.. Clin Cancer Res 30(15):3298-3315 PMID: 38772416
- 7. Gomatou G et al.. 2021. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.. Mol Biol Rep 48(1):915-925 PMID: 33409716
- 8. Yao Y et al.. 2023. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.. Blood 141(23):2841-2852 PMID: 36877894
